Americas Hospital Acquired Infection Testing Market
Americas Hospital Acquired Infection Testing Market Analysis By Test (MSRA, Clostridium difficile Testing Kits), By Modality (Immunoassay Testing, Point-of-care Testing), By Sample (Blood, Nasal Swabs, Urine, Stool), By End User, By Region - Global Insights 2021-2031
Analysis of Americas Hospital Acquired Infection Testing market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Americas Hospital Acquired Infection Testing Market Outlook
Fact.MR's Americas hospital acquired infection testing industry analysis predicts the market to attain a valuation of US$ 2.7 Bn by the end of the decade, which is more than 4X more than its worth at present. This research survey forecasts the market to expand at a significant CAGR of around 13% through 2031, with the U.S. slated to account for over 55% market share.
Demand Analysis of Hospital Acquired Infection Testing from 2016 to 2020 Compared to Market Outlook for 2021-2031
According to Fact.MR, a market research and competitive intelligence provider, the America’s hospital acquired infection testing market is valued at US$ 594.8 Mn in 2020, and has been expanding at a CAGR of 12.8% over the past five years.
Rise in incidence of hospital associated infections, increasing prevalence of chronic diseases, and government initiatives to control and create awareness regarding hospital acquired infections are expected to have a positive impact on market growth.
Also, increase in cases of surgical site infections will further augment growth of the hospital acquired testing industry. Rise in risk due to admission of COVID-19 patients has further created widespread demand for hospital acquired infection testing kits. Growth of the market is being further augmented by the introduction of new products.
Fact.MR expects the Americas hospital acquired infection testing market to surge at 15% CAGR through 2031.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
How are Rising Cases of Surgical Site Infections Impacting Market Growth?
Rise in surgical procedures are elevating the risk of contracting surgical site infections. Surgical site infections (SSIs) are the most commonly reported healthcare-acquired infections and surgical complication in both, developed and developing countries.
SSI can result in increased morbidity and mortality, prolonged hospital stay, increased hospital readmissions, and even reoperation and elevated costs.
According to a study, in the United States, SSI is found to be a serious complication with an incidence of 2%-5% in patients undergoing surgery, complicating approximately 300,000 to 500,000 surgeries per year and costing the healthcare system upward of US$ 1.6 Bn.
SSI leads to serious consequences, including increased costs due to its treatment and longer length of hospital stay, adding to the financial burden on patients.
Thus, growing incidence of surgical site infections will create demand for better diagnostics and treatment options, as such highlighting the importance of hospital acquired infection testing in the Americas.
What are the Key Opportunities for Hospital Acquired Infection Testing Kit Manufacturers?
Medical tourism in Latin American countries provides and array of opportunities for the growth of hospital acquired infection testing industry. Leading destinations industry include Mexico, Costa Rica, Brazil, and the Domination Republic, as these countries offer a range of healthcare services at affordable prices as compared to developed economies.
Increasing medical tourism is expected to aid the growth of emergency medicine services, including the use of ambulances, ambulatory surgical centers, and hospitals, which, in turn, will create demand for hospital acquired infection testing kits.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
What is Restraining Demand for Hospital Acquired Infection Testing in the Americas?
There are various barriers that service providers have to face while introducing new tests or kits in the market. One amongst these is stringent government regulations. Diagnostic kits that are developed by independent medical device manufacturers and sold to medical laboratories are subjected to strict regulatory guidelines and a lengthy FDA approval process.
Moreover, tightening of regulatory grip of the FDA on certain home-grown diagnostic kits further threatens to put a stranglehold on the development and implementation of innovative diagnostics by clinical laboratories in the U.S.
Thus, stringent regulatory guidelines are expected to restrain the growth of the HAIs testing market over the coming years.
How Lucrative is the Opportunity for Hospital Acquired Infection Testing Kit Manufacturers in the U.S.?
The U.S. is estimated to account for nearly 58% share in 2021, and represents the largest regional market in the Americas HAI testing market. Longer hospital stays and subsequent risk of developing HAIs are factors that are driving demand for HAI testing kits.
Also, significant awareness and focus on reducing hospital readmission rates through various awareness programs and high priority towards reducing economic burden caused by HAIs are providing lucrative opportunities regional market growth.
What are the Key Factors Enabling Growth of the Market for Hospital Acquired Infection Testing in Brazil?
Brazil accounted for over 32% market share of Latin America in 2020. Gradual improvement in healthcare in the country over the past decade has contributed to the growth of the market.
Additionally, rise in patient pool and growing medical tourism industry in the country are significant contributing factors for rising sales of hospital acquired infection test kits.
What is Scope of Growth for Hospital Acquired Infection Testing in Mexico?
The market for hospital acquired infection testing in Mexico is set to exhibit over 20% CAGR, and is expected to account for nearly 28% of the Latin American for hospital acquired infections (HAI) diagnostics market.
Emerging economies such as Mexico show significant potential to capitalize on the growth opportunities in this region, primarily due to continuous improvements in healthcare infrastructure and rising need for hospital acquired infection prevention.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Why is Demand for MRSA Kits on the Rise?
Followed by helicobacter pylori testing kits, MRSA kits are expected to account for the second-largest market share of 24%. High share of this test is primarily attributed to growing prevalence of hospital acquired MRSA infections.
Why are Blood Samples Preferred for Determining Hospital Acquired Infections?
Blood samples are the most preferred for determining HAIs. The segment is projected to expand at a CAGR of 12% during the forecast period. Growing cases of catheter-related blood stream infections due to prolonged hospital stays are anticipated to boost demand for blood sample testing.
Demand for urinary tract infection (UTI) testing is also seeing a notable rise, as is demand for methicillin-resistant staphylococcus aureus (MRSA) testing.
What is the Future Outlook for Immunoassay Testing?
Immunoassay testing will continue to grow at a significant rate at a CAGR of 16.7% during the study period. Ability of diagnostic laboratories to manage high sample volume is a key factor fueling the growth of this segment.
Further, diagnostic labs are well-equipped with advanced technological instruments that provide more accurate results. This is another factor that has had a positive impact on market growth.
What is Scope of Growth for Home Care Testing for Hospital Acquired Infections?
Despite diagnostic laboratories currently dominating the market with 35.8% value share, home care testing for hospital acquired infection control is expected to witness significant growth at 23% CAGR.
Demand for point-of-care testing owing to its rapid, accurate results with quick turnaround time is one of the key factors driving demand for home care testing of HAIs.
Apart from these, increasing ageing population demanding healthcare services, specimen stability and ease of handling, improved patient outcomes, reduction of unnecessary hospital visits, and improved patient outcome are some other factors contributing to higher growth of this end-user segment.
What Is the Impact of COVID-19 on Hospital Acquired Infection Testing in the Americas?
The COVID-19 pandemic is expected to have a moderately positive impact on the overall growth of the Americas HAIs testing market. Advancements in technologies have led to preference of point-of-care testing over conventional methods. This supported healthy growth in demand for point-of-care testing kits amid the pandemic.
The Americas hospital acquired disease testing market is marked by the presence of emerging as well as established market players. Need to reduce HAIs has motivated key players to launch new and innovative products in the market.
Further to strengthen their footprint in the Americas, key players are focused on pursing mergers and acquisitions as their key growth strategy.
- In December 2019, Hoffmann-La Roche Ltd. received FDA approval for the cobas vivoDx MRSA test, a diagnostic test based on bacterial viability and novel technology to detect methicillin-resistant Staphylococcus aureus (MRSA) bacterial colonization, a widespread cause of hospital-acquired infections. The test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples, in five hours.
Hospital Acquired Infection Testing Market Report Scope
Historical Data Available for
|USD Million for Value/ Units in Million for Volume|
Key Regions Covered
|North America and Latin America|
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
|Customization & Pricing||
Available upon Request
Segments as per Americas Hospital Acquired Infection Testing Industry Research
- MSRA Testing Kits
- MRSA Real-Time PCR Detection Kits
- MRSA Rapid Test Kits
- Staphylococcus aureus Detection Kits
- Staphylococcus aureus Latex Test Kits
- Staphylococcus aureus Assay Test Kits
- Clostridium difficile Testing Kits
- Clostridium difficile Detection Panels
- Clostridium difficile Immunoassay Kits
- Helicobacter pylori Testing Kits
- Helicobacter pylori Rapid Antigen Test Kits
- Helicobacter pylori IgG antibodies Test Kits
- Rotavirus/ Adenovirus Real-time PCR Kits
- RSV RT-PCR Test Kit
- RSV Ag Rapid Test Kits
- Strep A Rapid Testing Kits
- Strep B Rapid Testing Kits
- Mononucleosis Testing Kits
- Calprotectin Test Kits
- MSRA Testing Kits
- Immunoassay Testing
- Point-of-care Testing
- Nasal Swabs
By End User
- Diagnostic Laboratories
- Cancer Research Institutes
- Specialty Clinics
- Home Care Settings
- FAQs -
At present, the Americas hospital acquired infections testing market is worth US$ 595 Mn.
The market is expected to top US$ 2.7 Bn by the end of 2031 with sales revenue expected to register a CAGR of 15% over the same period.
From 2016-2020, the market expanded at the rate of 12.8%, owing to rise in incidence of hospital acquired infections.
Increasing mergers and acquisitions by leading players, new product launches, and approvals are some for the key trends shaping market expansion.
The U.S., Brazil, and Mexico are expected to drive increased demand for HAI testing over the next ten years.
North America is a key market for hospital acquired infection testing, with the U.S. expected to account for 58% market share through 2031.
Demand for hospital acquired infection testing is expected to register a growth rate of 19.5% in Latin America.
The market in Brazil will offer lucrative growth opportunities and is expected to exhibit a CAGR of 17%, while Mexico holds a revenue share of 28.3%.